Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alli Purchaser Characteristics Post-Label Revision
NCT02141230Withdrawn
- Sponsor
- GSK
- Start
- Dec 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of orlistat in obesity and Overweight, sponsored by GSK. Primary endpoints: Proportion of Alli® purchasers with a BMI <28 kg/m2 and Proportion of Alli® purchasers aged <18 years. Planned start Dec 2015; status: withdrawn.
02
Drugs
orlistat
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT02141230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141230.